The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A logic-gated chimeric antigen receptor T-cell (CAR T) therapy with an armored, membrane-tethered IL-12 booster in patients with advanced solid tumors with HLA-A*02 loss of heterozygosity (LOH): EVEREST-2, a phase 1/2 study.
 
Salman Punekar
Research Funding - A2 Biotherapeutics (Inst); Affini-T Therapeutics (Inst); Amgen (Inst); Astellas Pharma (Inst); Constellation Pharmaceuticals (Inst); NCI (Inst); Neogene Therapeutics (Inst); Prelude Therapeutics (Inst); Revolution Medicines (Inst); Simcere (Inst); Tango Therapeutics (Inst); VITRAC Therapeutics (Inst)
Travel, Accommodations, Expenses - Revolution Medicines
 
Sandip Patel
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; BeiGene; Bristol-Myers Squibb; Compugen; Iovance Biotherapeutics (Inst); Lilly; Lilly; Nektar; Novartis; Pfizer; Roche/Genentech; Tempus
Speakers' Bureau - Boehringer Ingelheim; Merck
Research Funding - A2Bio (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Fate Therapeutics (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst)
 
Gregory Botta
Stock and Other Ownership Interests - Natera
Honoraria - Merus; Natera
Consulting or Advisory Role - Natera
Speakers' Bureau - Natera
 
Jeffrey Ward
Employment - Pfizer (I)
Consulting or Advisory Role - AstraZeneca; Guidepoint Inc; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Novocure; Obsidian Therapeutics
Research Funding - A2 Biotherapeutics (Inst); Amgen (Inst); Asher Biotherapeutics (Inst); AstraZeneca (Inst); Biohaven Pharmaceuticals (Inst); BioNTech SE (Inst); Genmab (Inst); Harpoon therapeutics (Inst); Instil Bio (Inst); Merck (Inst); Novocure (Inst); Pfizer (Inst); Roche/Genentech (Inst); WindMIL (Inst)
Travel, Accommodations, Expenses - A2 Biotherapeutics; Novocure
 
Kedar Kirtane
Leadership - MyCareGorithm
Stock and Other Ownership Interests - Agenus; Oncternal Therapeutics; Veru
Consulting or Advisory Role - MyCareGorithm
Research Funding - Turnstone Bio
Travel, Accommodations, Expenses - A2Bio
 
Dhauna Prasad
No Relationships to Disclose
 
Alessandro Leal
Employment - Delfi Diagnostics
Stock and Other Ownership Interests - Delfi Diagnostics
Patents, Royalties, Other Intellectual Property - Delfi Diagnostics
Travel, Accommodations, Expenses - Delfi Diagnostics
 
Matthew Ulrickson
Consulting or Advisory Role - ADC Therapeutics; Autolus; Bristol-Myers Squibb/Celgene/Juno; Genentech; Kura Oncology; Stemline Therapeutics
Research Funding - Immunogen; Kite, a Gilead company
Travel, Accommodations, Expenses - Miltenyi Biotec
 
Jennifer Specht
Honoraria - BioNTech; Daiichi Sankyo; Scripps Research; Sensei Biotherapeutics
Consulting or Advisory Role - BioNTech; Boehringer Ingelheim; Daiichi Sankyo; GE Healthcare; Lyell Immunopharma Inc
Research Funding - A2 Biotherapeutics (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Biocity (Inst); Carisma Therapeutics (Inst); Celcuity (Inst); Genentech (Inst); Lyell Immunopharma (Inst); Merck (Inst); OnKure (Inst); Pfizer (Inst); Seagen (Inst); Xencor (Inst)
Patents, Royalties, Other Intellectual Property - UW CoMotion - Patent Royalty for ROR1 CAR (Inst)
Travel, Accommodations, Expenses - A2 Biotherapeutics; Dava Oncology; GE Healthcare; GlaxoSmithKline; iwCAR-T; Nektar
 
David Zhen
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Exelixis; Jazz Pharmaceuticals; Legend Biotech
Research Funding - A2 Biotherapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Clasp Therapeutics (Inst); Cornerstone Pharmaceuticals (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Genentech (Inst); Legend Biotech (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst)
 
Yanyan Lou
Consulting or Advisory Role - AstraZeneca; Janssen; Lilly; Turning Point Therapeutics
Research Funding - Blueprint Medicines (Inst); Daiichi-Sankyo (Inst); Genmab (Inst); Merck (Inst); Mirati Therapeutics (Inst); Roche/Genentech (Inst); Tolero Pharmaceuticals (Inst)
 
Monica Avila
No Relationships to Disclose
 
Kai He
Consulting or Advisory Role - AstraZeneca; BioNTech SE; Bristol-Myers Squibb; Iovance Biotherapeutics; Lyell Immunopharma; Mirati Therapeutics; Obsidian Therapeutics; oncoc4; Perthera; Pfizer; Synthekine
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Iovance Biotherapeutics (Inst); Mirati Therapeutics (Inst); Oncoc4 (Inst)
 
Oliver Dorigo
Honoraria - Blueprint Medicines
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; GlaxoSmithKline; IMV; Merck; PSI CRO Deutschland; R-Pharm
Speakers' Bureau - Immunogen
Research Funding - AstraZeneca (Inst); BioEclipse Therapeutics (Inst); EMD Serono (Inst); Genentech (Inst); IMV (Inst); Millennium (Inst); Novartis (Inst); PharmaMar (Inst)
 
Cathy Eng
Consulting or Advisory Role - Abbvie; Abbvie; Agenus; Amgen (I); Boehringer Ingelheim; Bristol Myers Squibb Foundation; EMD Serono; Gilead Sciences; GlaxoSmithKline; Incyte; Merck; Merus; Pfizer; Revolution Medicines; Taiho Oncology (I); Takeda
Research Funding - Gritstone Bio (Inst); Hutchison MediPharma (Inst); Janssen Oncology (Inst); Merck (Inst); Pfizer (Inst); Sumitomo Dainippon Pharma Oncology (Inst)
Travel, Accommodations, Expenses - Takeda
 
Jasmine Mitchell
No Relationships to Disclose
 
Armen Mardiros
Employment - A2 Biotherapeutics
Stock and Other Ownership Interests - A2 Biotherapeutics
 
John Welch
Employment - A2 Biotherapeutics
Leadership - A2 Biotherapeutics
Stock and Other Ownership Interests - A2 Biotherapeutics
Consulting or Advisory Role - Agios; Archer
Research Funding - Janssen Oncology (Inst); Notable Labs (Inst)
 
Julian Molina
No Relationships to Disclose
 
Joel Hecht
Stock and Other Ownership Interests - Actym Therapeutics; Johnson & Johnson (I); Rafael Pharmaceuticals; Trumvira
Consulting or Advisory Role - Agenus; ALX Oncology; BeiGene; Boehringer Ingelheim; Cardiff Oncology; Cartography; Civala; Curium Pharma; Fog Pharmaceuticals; Genmab; MBQ Pharma; Merus NV; Revolution Medicines; Urogen pharma; Xilio Therapeutics; Xilio Therapeutics
Research Funding - A2 Biotherapeutics (Inst); Affini-T Therapeutics (Inst); Agenus (Inst); Amgen (Inst); Bold Therapeutics (Inst); Camurus (Inst); Cardiff Oncology (Inst); CG Pharmaceuticals (Inst); Crinetics Pharmaceuticals (Inst); Exelixis (Inst); Gilead Sciences (Inst); Gritstone Bio (Inst); Janssen Oncology (Inst); Lyell Immunopharma (Inst); Merck (Inst); Mirati Therapeutics (Inst); Neogene Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Regeneron (Inst); Revolution Medicines (Inst); Seagen (Inst); Tizona Therapeutics, Inc. (Inst); Tizona Therapeutics, Inc. (Inst); Xilio Therapeutics (Inst)
Travel, Accommodations, Expenses - A2 Biotherapeutics